Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Lotensin Clear all

Conditions: Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia, Hypertension, Diabetes Mellitus, Type 2, Diabetes Mellitus, Coronary Disease
Interventions: Anti-hyperglycemic Agents, Anti-hypertensive Agents, Blinded fenofibrate or placebo plus simvastatin; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 40 Years to 79 Years
Enrollment: 10,251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2012
U.S. locations: 6
States / cities: Minneapolis, Minnesota • New York, New York • Winston-Salem, North Carolina + 3 more

Conditions: Hypertension, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: lisinopril, losartan potassium, laboratory biomarker analysis, benazepril hydrochloride, ramipril; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Hypertension
Interventions: amlodipine besylate/benazepril hydrochloride; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 259 participants
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Healthy
Interventions: Benazepril HCl 40 mg Tablets, Lotensin® 40 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hypertension
Interventions: amlodipine/benazepril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 1,422 participants
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Microalbuminuria
Interventions: benazepril; Drug
Lead sponsor: Charles Drew University of Medicine and Science; Other
Eligibility: 18 Years to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension, Left Ventricular Hypertrophy
Interventions: amlodipine/benazepril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 55 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Healthy
Interventions: Benazepril HCl 40 mg Tablets, Lotensin® 40 mg Tablets; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy
Interventions: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: Amlodipine and Benazepril HCl Capsules 10 mg/20 mg, Lotrel® Capsules 10 mg/20 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 84 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Temple, Texas

Conditions: Healhty
Interventions: Amlodipine and Benazepril HCl Capsules 10 mg/20 mg, Lotrel® Capsules 10 mg/20 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Healthy
Interventions: Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Healthy
Interventions: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg, Lotensin HCT® Tablets 20 mg/25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hypotension on Induction
Interventions: ACEI continuation, ACEI omission; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 90 Years
Enrollment: 291 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Adverse Effects of Angiotensin-converting-enzyme Inhibitors, Hypotension
Interventions: ACE-I Cessation group, ACE-I Continuation group; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg, Lotensin HCT® Tablets 20 mg/25 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Hypertension
Interventions: Amlodipine/benazepril; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 275 participants
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension
Interventions: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter, Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1, Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2, Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter; Drug
Lead sponsor: Novartis; Industry
Eligibility: 55 Years and older
Enrollment: 11,506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: East Hanover, New Jersey

Search by objective public record fields.

Action to Control Cardiovascular Risk in Diabetes (ACCORD)

Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors

Study Comparing the Efficacy of Amlodipine Besylate/Benazepril Versus Amlodipine in the Treatment of Severe Hypertension

Benazepril HCl 40 mg Tablets, Fed

A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.

Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria

Effects of Amlodipine/Benazepril in Reducing Left Ventricular Hypertrophy in Patients With High Risk Hypertension

Benazepril HCl 40 mg Tablets, Fasting

Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fasting Conditions

Fasting Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Fed Study of Amlodipine and Benazepril HCl Capsules 10 mg/20 mg to Lotrel® Capsules 10 mg/20 mg

Bioequivalence Study of Benazepril HCl / Hydrochlorothiazide 20 mg/ 25 mg Tablets Under Fed Conditions

Fasting Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg

Chronic Angiotensin Converting Enzyme Inhibitors in Intermediate Risk Surgery

ACE-Inhibitor Effects on Total Hip and Knee Arthroplasty Patients

Fed Study of Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg to Lotensin HCT® Tablets 20 mg/25 mg

Effects of Amlodipine/Benazepril in the Hypertensive African-American Population With Type 2 Diabetes Mellitus

Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension